18F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models

@article{Yang201718F5FluoroaminosubericAA,
  title={18F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models},
  author={Hua Yang and Silvia Jenni and Milena {\vC}olovi{\'c} and Helen Merkens and Carlee Poleschuk and Isabel Rodrigo and Qing Miao and Bruce F Johnson and Michael James Rishel and Vesna Sossi and Jack M. Webster and François B{\'e}nard and Paul Schaffer},
  journal={The Journal of Nuclear Medicine},
  year={2017},
  volume={58},
  pages={367 - 373}
}
The cystine transporter (system xC−) is an antiporter of cystine and glutamate. It has relatively low basal expression in most tissues and becomes upregulated in cells under oxidative stress (OS) as one of the genes expressed in response to the antioxidant response element promoter. We have developed 18F-5-fluoroaminosuberic acid (FASu), a PET tracer that targets system xC−. The goal of this study was to evaluate 18F-FASu as a specific gauge for system xC− activity in vivo and its potential for… 

Figures and Tables from this paper

Non-invasive Use of Positron Emission Tomography to Monitor Diethyl maleate and Radiation-Induced Changes in System xC− Activity in Breast Cancer
TLDR
FASu is a specific system xC− PET radiotracer and as such it can be used to monitor system x C− activity due to OS and has the potential to be used in therapy response monitoring by PET.
The Characterization of 18F-hGTS13 for Molecular Imaging of xC− Transporter Activity with PET
TLDR
18F-hGTS13-isomer2 is a new PET radiotracer for molecular imaging of xC− activity that may provide information on tumor oxidation states and has potential for clinical translation for imaging cancers of the thorax because of the low background signal in healthy tissue.
Assessment of Tumor Redox Status through (S)-4-(3-[18F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc - Activity.
TLDR
It is shown that tumor cell retention of a system xc --specific PET radiotracer, (S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([ 18F]FSPG), decreases in proportion to levels of oxidative stress following treatment with a range of redox-active compounds.
The Effect of Chirality on the Application of 5-[18F]Fluoro-Aminosuberic Acid ([18F]FASu) for Oxidative Stress Imaging
TLDR
The data suggest that pure 2S-[18F]FASu can be used to noninvasively image system xC- in a variety of cancers, either as the racemic mixture (2S,5R/S-) or optically pure form.
Addressing Chirality in the Structure and Synthesis of [18 F]5-Fluoroaminosuberic Acid ([18 F]FASu).
TLDR
This study serves as an example of a systematic method to identify and characterize amino acid tracers with chiral centers, and synthesizing pure 2S,5R/S-FASu with fully known configuration.
Imaging of innate immunity activation in vivo with a redox-tuned PET reporter.
TLDR
4-Fluoro-1-naphthol shows promise as a robust reporter of innate immunity activation by PET/CT and 4-ABAH and Cybb-/- (Nox2-/-) gene deletion strongly abrogated [18F]4FN retention in vivo.
Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
TLDR
18F-FSPG is a promising tumor imaging agent for PET that seems to have favorable biodistribution and high cancer detection rate in patients with prostate cancer.
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
TLDR
A mechanism by which oncogenic RAS preserves intracellular redox balance is uncovers and an unexpected role for xCT is identified in supporting RAS-induced transformation and tumorigenicity is identified.
...
1
2
3
...

References

SHOWING 1-10 OF 30 REFERENCES
The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
TLDR
The results suggest that the xc− transporter by enhancing glutathione biosynthesis plays a major role in pancreatic cancer growth, therapy resistance and represents a potential therapeutic target for the disease.
Functional Imaging of Oxidative Stress with a Novel PET Imaging Agent, 18F-5-Fluoro-l-Aminosuberic Acid
TLDR
The synthesis and in vitro and in vivo validation of a lead candidate, 18F-5-fluoro-aminosuberic acid (18F-FASu), as a PET tracer for functional imaging of a cellular response to oxidative stress with remarkable tumor uptake and retention are reported.
Pharmacogenomic Approach Reveals a Role for the xc− Cystine/Glutamate Antiporter in Growth and Celastrol Resistance of Glioma Cell Lines
TLDR
Results indicate that the xc− transporter provides a useful target for glioma therapy and may be effective both as an anticancer drug and as an agent for sensitizing gliomas to celastrol.
Sulfasalazine-Induced Reduction of Glutathione Levels in Breast Cancer Cells: Enhancement of Growth-Inhibitory Activity of Doxorubicin
TLDR
SASP-induced reduction of cellular GSH levels can lead to growth arrest of mammary cancer cells and enhancement of anticancer drug efficacy.
Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma
TLDR
Using an immune-deficient xenograft model, it is demonstrated that an xCT selective inhibitor, Sulfasalazine (SASP), prevents PEL tumor progression in vivo and provides innovative and mechanistic insights into the role of xCT in PEL pathogenesis, and the framework for xCT-focused therapies for AIDS-related lymphoma in future.
Specific PET Imaging of xC− Transporter Activity Using a 18F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism
TLDR
BAY 94-9392 is a new tumor-specific PET tracer which could be useful to examine system xC− activity in vivo as a possible hallmark of tumor oxidative stress.
Enhancement of L-cystine transport activity and its relation to xCT gene induction at the blood-brain barrier by diethyl maleate treatment.
TLDR
L-Cystine transport via system x(c)(-)- at the BBB is likely to be induced under oxidative stress conditions following DEM treatment due to enhanced transcription of the xCT gene.
Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas
TLDR
Cellular redox state markers may be promising targets when elucidating the pathogenesis of TNBC and BLBC.
System xc‐ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS
TLDR
The current status of the understanding of system xc‐ pharmacology and the structure–activity relationships that have guided the development of an initial pharmacophore model are examined, including the presence of lipophilic domains adjacent to the substrate binding site.
...
1
2
3
...